TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu


The Neurodegeneration cluster portfolio consists of research on adult onset neurodegenerative diseases of all types, broadly focusing on pathogenesis, treatment and prevention. Research on the normal structure and function of neural systems is also included to enable identification of intervention strategies. The role of the programmatic team is to develop, implement and manage these research programs and to promote the translation of research findings into clinical practice.  Included in the portfolio are topics such as neuronal cell death, protein misfolding, aggregation, processing, mitochondrial pathologies, epidemiological studies, genetic studies, biomarker studies, clinical studies, including deep brain stimulation and gene therapy, and translational projects that will accelerate bench-to-bedside therapies for neurodegenerative disorders.

Quick Links

Workshop Summary

Neurodegeneration Funding Initiatives and Requests for Information

  • The NINDS Human Biomarkers Biospecimen and Data Repository (U24) RFA-NS-15-010. The NINDS is soliciting applications for a Human Biospecimen and Data Repository for Biomarkers Research ("Biomarkers Repository") in Neurological Disorders. Collaborative teams combining expertise in neuroscience, biomarkers, biospecimen handling, and data management are encouraged to apply. Experience in biomarker research, such as evaluation of batch effects, protocol development, and analyte quality control measures, is expected. Successful applications will include a detailed description of 1) Administrative Structure, 2) Research and Resource Plan, and 3) Data Management and Web-Based activities. Letter of intent due date: May 9, 2015. Application receipt date: June 9, 2015. Contact: Katrina Gwinn, M.D.
  • The NINDS Human Cell and Data Repository (U24) RFA-NS-15-009. The purpose of this FOA is to support the expansion of the NINDS Human Cell and Data Repository. The repository will maintain the current collection of fibroblast and induced pluripotent stem cell (iPSC) lines as well as develop, characterize, expand and where appropriate genetically modify new high-quality iPSC, fibroblast cell lines and peripheral blood monocyte cells in accordance with the NINDS mission. The NINDS Human Cell and Data Repository will distribute human cell resources broadly to qualified academic and industry researchers. Letter of intent due date: May 9, 2015. Application receipt date: June 9, 2015. Contact: Marg Sutherland, Ph.D.
  • Request to Access Parkinson's Disease Related-Biospecimens (X01) PAR-14-340. Applications to this X01 have a rolling submission. Submissions between March 16 - May 15, 2015 have a review date between May 25 - June 5, 2015. Submissions between May 16 - July 15, 2015 have a review date between July 25 - August 5, 2015. Submissions between July 16 - September 15, 2015 have a review date between September 25 - October 5, 2015. Submissions between September 16 - November 15, 2015 have a review date between November 25 - December 5. Contact: Katrina Gwinn, M.D., Marg Sutherland, Ph.D.
  • Parkinson's Disease Biomarker Program (PDBP) Discovery Projects (U01) PAR-NS-14-259. The purpose of this funding opportunity announcement (FOA) is to support up to three years of study for the discovery, assay optimization, and replication stages required for the development of biological biomarkers for Parkinson's disease (PD). Application receipt date(s): May 4, 2015, September 4, 2015, February 4, 2016, May 4, 2016, by 5:00 PM local time of applicant organization. Contact: Katrina Gwinn, M.D., Marg Sutherland, Ph.D.
  • NINDS Translational Research Opportunities:


In the News


Neurodegeneration Program Staff

Scientific StaffResearch Area
Roderick Corriveau, Ph.D.
Program Director
Point of contact: AD, vascular dementias, hereditary spastic paraplegia
Alzheimer’s disease, vascular dementias, and hereditary spastic paraplesia. For Alzheimer’s disease research, studies focused on molecular mechanisms of disease pathophysiology with areas of emphasis including but not limited to: (1) APP, beta-amyloid, presenilins, tau, neurotrophins and synaptic proteins; (2) animal models; (3) neuroinflammation; (4) post-translational protein modifications; (5) protein trafficking and clearance.
Amelie Gubitz, Ph.D.
Program Director
Point of contact: ALS, SBMA (Kennedy's Disease), HSP
Basic, translational, and clinical research studies of amyotrophic lateral sclerosis (ALS), X-linked spinal and bulbar muscular atrophy (SBMA, Kennedy's Disease), and hereditary spastic paraplegia (HSP).
Daniel Miller, Ph.D.
Program Director
Basic and translational studies of Huntington's disease (HD).
Beth-Anne Sieber, Ph.D.
Program Director
Point of contact: PD, parkinsonisms, dystonia
Parkinson’s disease (PD), including molecular biology, cell biology, neurochemistry, deep brain stimulation (DBS), gene therapy, motor and non-motor manifestations. Parkinsonian disorders including multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), and dystonia.
Margaret Sutherland, Ph.D.
Program Director
Point of contact: HD, FTD
Clinical research studies of Huntington’s disease (HD), frontotemporal dementia (FTD), Parkinson’s disease (PD), genome-wide association (GWA) studies, genetics, biomarkers, stem cells, protein and mitochondrial dynamics, translational research, and clinical trials.
Christine R. Swanson-Fischer, Ph.D.
Health Program Specialist

Jordan Gladman, Ph.D.
Health Program Specialist



Neuroscience Center
6001 Executive Blvd.
Bethesda, Maryland 20892